Eagle pharmaceuticals, inc. (EGRX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Sep'14Sep'13Sep'12
Revenue:
Total revenue

195,892

213,312

236,707

189,482

66,227

19,099

13,679

2,539

Operating expenses:
Cost of product sales

47,891

42,374

33,714

35,785

7,762

5,042

-

-

Cost of royalty revenue

13,006

19,542

23,472

19,521

7,885

6,672

7,381

3,166

Research and development

36,810

44,419

32,607

28,289

27,855

16,816

9,795

12,805

Selling, general and administrative

76,370

60,509

71,416

53,329

20,165

9,326

4,958

6,399

Restructuring charge

0

7,911

0

0

-

-

-

-

Gain on sale of asset

-

-

-

1,750

0

0

-

-

Asset impairment charge

0

2,704

7,235

0

0

-

-

-

Change in fair value of contingent consideration

0

-763

-7,377

957

0

-

-

-

Legal settlement

0

0

1,650

0

0

-

-

-

Total operating expenses

174,077

176,696

162,717

136,131

63,667

37,856

22,134

22,370

Income from operations

21,815

36,616

73,990

53,351

2,560

-18,757

-8,455

-19,831

Interest income

2,169

158

91

84

25

31

3

34

Interest expense

2,686

2,736

1,136

8

11

8

309

91

Amortization of deferred financing costs

-

-

-

-

-

-

96

19

Amortization of debt discount

-

-

-

-

-

-

1,091

218

Net proceeds from arbitration

-

-

-

-

-

-

4,050

0

Loss on subscription loan settlement

-

-

-

-

-

-

-

-51

Change in value of warrant liability

-

-

-

-

-

573

1,052

0

Other expense

700

0

0

-

-

35

3

12

Total other expense, net

183

-2,578

-1,045

76

14

-515

1,508

-333

(Loss) Income before income tax benefit (provision)

21,998

34,038

72,945

53,427

2,574

-19,272

-6,947

-20,164

Income tax benefit (provision)

7,685

2,135

21,002

-28,026

3

-1,295

-899

-781

Less dividends on Series A, B, B-1 and C Convertible Preferred Stock

-

-

-

-

-

1,666

3,837

3,933

Net income

14,313

31,903

-

-

-

-19,643

-9,885

-23,316

Net (Loss) Income

14,313

31,903

51,943

81,453

2,571

-17,977

-6,048

-19,383

(Loss) Earnings per share attributable to common stockholders:
Basic (in usd per share)

1.04

2.16

3.44

5.24

0.17

-1.97

-3.25

-

Diluted (in usd per share)

1.01

2.09

3.27

4.96

0.16

-1.97

-3.25

-

Weighted average number of common shares outstanding:
Basic (in shares)

13,754

14,768

15,102

15,533

15,250

9,955

3,044

-

Diluted (in shares)

14,138

15,278

15,908

16,434

16,253

9,955

3,044

-

Loss per share attributable to common stockholders Basic and diluted (in usd per share)

-

-

-

-

-

-

-

-14.11

Weighted average common shares outstanding Basic and diluted

-

-

-

-

-

-

-

1,652

Product sales
Total revenue

73,989

70,385

45,327

40,646

12,968

4,626

5,315

1,155

Royalty revenue
Total revenue

112,903

142,927

153,880

99,040

8,259

10,708

8,364

1,384

License and other revenue
Total revenue

9,000

0

37,500

49,796

45,000

3,765

0

0